APA (7th ed.) Citation

SK, M. (2023). ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Annals of surgical oncology, 30(11), 6567. https://doi.org/10.1245/s10434-023-13811-x

Chicago Style (17th ed.) Citation

SK, Maithel. "ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma." Annals of Surgical Oncology 30, no. 11 (2023): 6567. https://doi.org/10.1245/s10434-023-13811-x.

MLA (9th ed.) Citation

SK, Maithel. "ASO Author Reflections: NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma." Annals of Surgical Oncology, vol. 30, no. 11, 2023, p. 6567, https://doi.org/10.1245/s10434-023-13811-x.